Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary
Jubilant Pharmova Limited
-(JUBLPHARMA)
XNSE:JUBLPHARMA, XBOM:JUBLPHARMA
Jubilant Pharmova Ltd Q1 FY24; 87% fall in Profits
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary
Jubilant Pharmova Q4FY23 Earnings Story
The three business components of Jubilant Pharmova Ltd, which include medicines, contract research and development services, and patented new therapies, make up
Jubilant Pharmova Q4FY23; Reported Losses
Jubilant Pharmova Ltd.’s revenue in Q4FY23 rose 10% to ₹ 1,678 crores. Consolidated Loss After Tax came at ₹ 101 crores in
Can Jubilant Pharmova leverage their position?
“In FY24, Company’s profitability is expected to improve, driven by growth in Radiopharmaceuticals, Allergy Immunotherapy and CDMO Sterile Injectables businesses. Recovery in
Earnings Summary Of Jubilant Pharmova Limited For Q3 FY23
Jubilant Pharmova Limited (NSE: JUBLPHARMA) was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in
Jubilant Pharmova Limited (JUBLPHARMA ) Q3 FY23 Earnings Concall Transcript
Jubilant Pharmova Limited (NSE:JUBLPHARMA) Q3 FY23 Earnings Concall dated Feb. 03, 2023. Corporate Participants: Vineet Mayer -- Investor Relations and Corporate Finance Shyam S
Jubilant Pharmova Limited Q3 FY23; Revenue Increased By 18%
Jubilant Pharmova Limited (NSE: JUBLPHARMA) reported a Revenue from Operations of ₹1,533.22 Crores, a boost of 18% growth from the previous year.
Jubilant Pharmova reports dip in its net profit by 97% for Q2FY23
Jubilant Pharmova reported total income of INR 1,599.5 crores during the period ended September 30, 2022 as compared to INR 1,657.7 crores
Jubilant Pharmova Limited (JUBLPHARMA) Q2 FY23 Earnings Concall Transcript
Jubilant Pharmova Limited (NSE:JUBLPHARMA) Q2 FY23 Earnings Concall dated Oct. 21, 2022 Corporate Participants: Surajit Pal -- Head, Investor Relations Shyam S
Everything you need to know about Jubilant Pharmova
About Company and its Outlook: Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research
Jubilant Pharmova reports dip in its net profit by 71% for Q1FY23
Jubilant Pharmova reported total income of INR 1,452 crores during the period ended June 30, 2022 as compared to INR 1,635 crores
Jubilant Pharmova Limited Q3 FY22 Earnings Conference Call Insights
https://www.youtube.com/watch?v=wOzoHVd4itc Key highlights from Jubilant Pharmova Limited (JUBLPHARMA) Q3 FY22 Earnings Concall Management Update: JUBLPHARMA stated that its performance during 3Q was